Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Rajkumar

Showing results (271-280 of 773) with videos related to

Pageof 78
Sort By:
Blood|March 28, 2012
Progression in smoldering Waldenstrom macroglobulinemia: long-term resultsRobert A Kyle, Joanne T Benson, Dirk R Larson, et al.
The Lancet. Haematology|December 23, 2014
Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort studyRobert A Kyle, Dirk R Larson, Terry M Therneau, et al.
Blood|November 15, 2013
Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significanceJoshua N Farr, Wei Zhang, Shaji K Kumar, et al.
Experimental Hematology|March 19, 2008
R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cellsMichael P Kline, S Vincent Rajkumar, Michael M Timm, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 8, 2026
The International Myeloma Society Honors the Life and Legacy of Myeloma Pioneer Brian G. M. Durie, MD, PhD (1942-2025)Philippe Moreau, Shaji Kumar, Noopur S Raje, et al.
Blood Cancer Journal|December 15, 2019
Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurementDavid Murray, Shaji K Kumar, Robert A Kyle, et al.
American Journal of Hematology|January 10, 2018
Reply to Castillo et alJithma P Abeykoon, Rebecca King, Stephen M Ansell, et al.
Blood Advances|May 14, 2025
Extramedullary Myeloma is Genomically Complex and Characterized by Near-Universal MAPK Pathway AlterationsSaurabh Zanwar, Joseph Novak, Wilson I Gonsalves, et al.
British Journal of Haematology|March 17, 2026
Preferred standard-of-care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologistsRahul Banerjee, Sharlene Dong, Georgia McCaughan, et al.
Mayo Clinic Proceedings|March 3, 2010
Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myelomaSumit Madan, Angela Dispenzieri, Martha Q Lacy, et al.
Pageof 78

Showing results (271-280 of 773) with videos related to

Sort By:
Pageof 78
Blood|March 28, 2012
Progression in smoldering Waldenstrom macroglobulinemia: long-term resultsRobert A Kyle, Joanne T Benson, Dirk R Larson, et al.
The Lancet. Haematology|December 23, 2014
Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort studyRobert A Kyle, Dirk R Larson, Terry M Therneau, et al.
Blood|November 15, 2013
Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significanceJoshua N Farr, Wei Zhang, Shaji K Kumar, et al.
Experimental Hematology|March 19, 2008
R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cellsMichael P Kline, S Vincent Rajkumar, Michael M Timm, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 8, 2026
The International Myeloma Society Honors the Life and Legacy of Myeloma Pioneer Brian G. M. Durie, MD, PhD (1942-2025)Philippe Moreau, Shaji Kumar, Noopur S Raje, et al.
Blood Cancer Journal|December 15, 2019
Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurementDavid Murray, Shaji K Kumar, Robert A Kyle, et al.
American Journal of Hematology|January 10, 2018
Reply to Castillo et alJithma P Abeykoon, Rebecca King, Stephen M Ansell, et al.
Blood Advances|May 14, 2025
Extramedullary Myeloma is Genomically Complex and Characterized by Near-Universal MAPK Pathway AlterationsSaurabh Zanwar, Joseph Novak, Wilson I Gonsalves, et al.
British Journal of Haematology|March 17, 2026
Preferred standard-of-care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologistsRahul Banerjee, Sharlene Dong, Georgia McCaughan, et al.
Mayo Clinic Proceedings|March 3, 2010
Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myelomaSumit Madan, Angela Dispenzieri, Martha Q Lacy, et al.
Pageof 78